Podcast: Silicon Valley's FDA
Executive Summary
Perspectives on two individuals – James O’Neill and Balaji Srinivasan – under review for potential high-level posts at the US agency, plus lessons learned from how FDA topsiders have been selected in the past.
Ramsey Baghdadi, Michael McCaughan, and Cole Werble discuss James O’Neill and Balaji Srinivasan, two potential candidates for high-level positions at FDA who met with President Trump shortly before his swearing in.
They also note key issues awaiting new agency leaders, and look to previous administrations for perspectives on the dynamics of selecting top officials and how quickly change can be affected by a new regime.
Listen to the podcast via the player below.
From the editors of the RPM Report.
For more on HHS agency leadership in the Trump administration:
- (Also see "NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’" - Pink Sheet, 24 Jan, 2017.)
- (Also see "Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking" - Pink Sheet, 12 Jan, 2017.)
- (Also see "Trump Takes Office, Change At US FDA Arrives With ‘Beachhead Teams’" - Pink Sheet, 19 Jan, 2017.)